4.5 Article

Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson's disease

Journal

NEUROBIOLOGY OF AGING
Volume 97, Issue -, Pages -

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2020.07.002

Keywords

Parkinson's disease; Genetic modifiers; Parkinsonism; Leucine-rich repeat kinase 2

Funding

  1. Parkinson's UK [J-1101, H-1703]
  2. University College London (UCL)
  3. NIHR Rare Diseases Translational Research Consortium
  4. Medical Research Council (MRC) [MR/N026004/1]
  5. Intramural Research Programs of the National Institute of Neurological Disorders, and Stroke (NINDS)
  6. National Institute on Aging (NIA)
  7. DRI Ltd
  8. UK Medical Research Council
  9. Alzheimer's Society
  10. Alzheimer's Research UK
  11. Wellcome Trust Hardy [202903/Z/16/Z]
  12. Dolby Family Fund
  13. National Institute for Health Research University College London Hospitals Biomedical Research Centre
  14. BRCNIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust
  15. University College London
  16. MRC [G1100643, MR/K01417X/1, G0901254, MR/N026004/1, UKDRI-1009, G0700943, G0701075] Funding Source: UKRI

Ask authors/readers for more resources

The LRRK2 gene is associated with rare and common risk variants for Parkinson's disease, while DNM3 and VAMP4 may also play a role in disease risk. However, more research is needed to understand the specific mechanisms involved.
The LRRK2 gene has rare (p.G2019S) and common risk variants for Parkinson's disease (PD). DNM3 has previously been reported as a genetic modifier of the age at onset in PD patients carrying the LRRK2 p.G2019S mutation. We analyzed this effect in a new cohort of LRRK2 p.G2019S heterozygotes (n = 724) and meta-analyzed our data with previously published data (n = 754). VAMP4 is in close proximity to DNM3, and was associated with PD in a recent study, so it is possible that variants in this gene may be important. We also analyzed the effect of VAMP4 rs11578699 on LRRK2 penetrance. Our analysis of DNM3 in previously unpublished data does not show an effect on age at onset in LRRK2 p.G2019S carriers; however, the inter-study heterogeneity may indicate ethnic or population-specific effects of DNM3. There was no evidence for linkage disequilibrium between DNM3 and VAMP4. Analysis of sporadic patients stratified by the risk variant LRRK2 rs10878226 indicates a possible interaction between common variation in LRRK2 and VAMP4 in disease risk. (C) 2020 The Authors. Published by Elsevier Inc.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available